Hormones (Athens, Greece) · 2026
RET Lys666Asn has a low rate of MEN2-related tumors but may be associated with pheochromocytoma.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Halperin Reut, Peshes-Yaloz Naama, Tirosh Amit, Twito Orit
Аннотация
PURPOSE: Multiple endocrine neoplasia type 2 (MEN2) is caused by germline pathogenic variants (PVs) in the RET proto-oncogene, leading to medullary thyroid carcinoma (MTC), pheochromocytoma, and primary hyperparathyroidism (PHPT). RET p.Lys666Asn is a rare PV, but its clinical significance remains incompletely understood. The purpose of this study is to expand the clinical understanding of the RET Lys666Asn variant.
METHODS: Index patients carrying the RET Lys666Asn variant were identified through clinical genetic testing in two referral medical centers. Comprehensive clinical evaluation, biochemical screening, and imaging studies were performed to assess the presence of MTC, pheochromocytoma, and PHPT of the index patients and carrier family members. We performed a literature search on Lys666Asn carriers and their clinical manifestations.
RESULTS: Ten individuals from five families were identified as carriers of the RET Lys666Asn variant. The median age at diagnosis was 43.7 years (range 2–75 years). Only one individual presented with pheochromocytoma, diagnosed at age 54. The rate of MTC, pheochromocytoma, and PHPT was 0 (0–0.26), 0.1 (0.01–0.39), and 0 (0–0.26), respectively. In a pooled analysis of cases reported in the literature, MTC, pheochromocytoma, and PHPT rate are 0.42 (0.28–0.57), 0.11 (0.04–0.22), and 0.03 (0–0.12), respectively. MTC had a wide age range at presentation (20–70 years).
CONCLUSION: The RET Lys666Asn variant is associated with lower event rate of MEN2-related tumors compared to classical MEN2 variants, particularly MTC and pheochromocytoma. Despite its rarity, pheochromocytoma cannot be excluded in carriers, underscoring the need for individualized screening protocols based on specific RET variants.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s42000-026-00759-2.
METHODS: Index patients carrying the RET Lys666Asn variant were identified through clinical genetic testing in two referral medical centers. Comprehensive clinical evaluation, biochemical screening, and imaging studies were performed to assess the presence of MTC, pheochromocytoma, and PHPT of the index patients and carrier family members. We performed a literature search on Lys666Asn carriers and their clinical manifestations.
RESULTS: Ten individuals from five families were identified as carriers of the RET Lys666Asn variant. The median age at diagnosis was 43.7 years (range 2–75 years). Only one individual presented with pheochromocytoma, diagnosed at age 54. The rate of MTC, pheochromocytoma, and PHPT was 0 (0–0.26), 0.1 (0.01–0.39), and 0 (0–0.26), respectively. In a pooled analysis of cases reported in the literature, MTC, pheochromocytoma, and PHPT rate are 0.42 (0.28–0.57), 0.11 (0.04–0.22), and 0.03 (0–0.12), respectively. MTC had a wide age range at presentation (20–70 years).
CONCLUSION: The RET Lys666Asn variant is associated with lower event rate of MEN2-related tumors compared to classical MEN2 variants, particularly MTC and pheochromocytoma. Despite its rarity, pheochromocytoma cannot be excluded in carriers, underscoring the need for individualized screening protocols based on specific RET variants.
SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at https://doi.org/10.1007/s42000-026-00759-2.